BioXcel Therapeutics, Inc.
BioXcel Therapeutics develops medicines for neuroscience and immuno-oncology using an AI platform to identify new therapeutic uses for existing drugs. The company's lead product, IGALMI® (dexmedetomidine sublingual film), is FDA-approved for acute agitation in schizophrenia and bipolar disorder, with ongoing trials for at-home use and Alzheimer's disease.
BioXcel Therapeutics, Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $40.1M market cap.
BTAI missed consensus EPS by 0.1% in Q1 FY2026, reported May 14, 2026.
14 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Spoken Alpha tracks BTAI's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 80% of the time
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BTAI.
$ curl https://api.spokenalpha.com/v1/companies/BTAIFAQ
Spoken Alpha indexes BTAI's earnings call transcripts at https://spokenalpha.com/companies/BTAI. Each call links to attributed speakers and parsed analyst Q&A. BioXcel Therapeutics, Inc.'s own investor relations page is at https://ir.bioxceltherapeutics.com/.
BioXcel Therapeutics, Inc. (BTAI) held its most recent earnings call on 2024-11-14, covering fiscal Q3 2024.
BioXcel Therapeutics, Inc. (BTAI) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-14 | $-0.54 | $-0.48 | -11.3% | $206.0K | — | — | EODHD |
| Q4 FY2025 | 2026-03-26 | $-1.03 | $-0.64 | -61.8% | $256.0K | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-2.18 | $-0.09 | -100.0% | $98.0K | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-2.45 | $-0.13 | -100.0% | $120.0K | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-1.50 | $-3.04 | +50.7% | $168.0K | — | — | EODHD |
| Q4 FY2024 | 2025-03-09 | $-3.56 | $-5.14 | +30.7% | $366.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.32 | $-0.54 | +40.7% | $214.0K | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $-0.21 | $-0.71 | +70.4% | $1.1M | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.87 | $-0.70 | -24.3% | $582.0K | — | — | EODHD |
| Q4 FY2023 | 2024-03-11 | $-0.76 | $-0.91 | +16.5% | $376.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-1.72 | $-1.30 | -32.3% | $341.0K | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-1.83 | $-1.75 | -4.6% | $457.0K | — | — | EODHD |
| Q1 FY2023 | 2023-05-07 | $-1.84 | $-1.62 | -13.6% | $206.0K | — | — | EODHD |
| Q4 FY2022 | 2023-03-08 | $-1.95 | $-1.45 | -34.5% | $238.0K | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-1.49 | $-1.35 | -10.4% | $137.0K | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $-1.35 | $-1.22 | -10.7% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-08 | $-1.12 | $-1.15 | +2.6% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-09 | $-0.93 | $-1.10 | +15.4% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-09 | $-0.96 | $-1.05 | +8.6% | $14.9K | — | — | EODHD |
| Q2 FY2021 | 2021-08-09 | $-1.11 | $-1.08 | -2.8% | $14.1K | — | — | EODHD |
Source: EODHD. BTAI reported actuals as published; sparse fields render as —.
When a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2024 | $0.57 | $0.47 | +21.0% | -9.4% | -10.6% |
| Q4 FY2024 | $0.89 | $0.77 | +15.1% | +2.0% | +1.4% |
| Q3 FY2024 | $0.70 | $0.65 | +7.5% | -7.4% | -5.9% |
| Q2 FY2024 | $0.75 | $0.66 | +14.2% | -1.8% | -2.8% |
| Q1 FY2023 | $0.75 | $0.65 | +15.8% | -7.2% | -9.6% |
CFO since 2025 • 2/2 beats (100%) • last guidance cut Q3 FY2024
| Q4 FY2023 |
| $0.94 |
| $0.81 |
| +16.5% |
| -1.0% |
| -1.9% |
| Q3 FY2023 | $0.76 | $0.63 | +20.8% | +0.9% | -1.7% |
| Q2 FY2023 | $0.84 | $0.76 | +10.2% | -8.0% | -5.8% |
| Q1 FY2022 | $0.95 | $0.78 | +21.2% | -6.0% | -5.3% |
| Q4 FY2022 | $1.04 | $0.90 | +16.0% | -1.0% | +1.2% |